Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
T. D. Filippatos, E. Klouras, F. Barkas & M. Elisaf. (2016) Cholesteryl ester transfer protein inhibitors: challenges and perspectives. Expert Review of Cardiovascular Therapy 14:8, pages 953-962.
Read now
Read now
Anthony D Pisaniello, Daniel J Scherer, Yu Kataoka & Stephen J Nicholls. (2015) Ongoing challenges for pharmacotherapy for dyslipidemia. Expert Opinion on Pharmacotherapy 16:3, pages 347-356.
Read now
Read now
Amit S. Kalgutkar, Kosea S. Frederick, Heather L. Hatch, Catherine M. Ambler, David A. Perry, Ravi S. Garigipati, George C. Chang, Bruce A. Lefker, Ronald W. Clark, Lee A. Morehouse, Omar Francone & Xiao Hu. (2014) Identification of a novel, non-tetrahydroquinoline variant of the cholesteryl ester transfer protein (CETP) inhibitor torcetrapib, with improved aqueous solubility. Xenobiotica 44:7, pages 591-605.
Read now
Read now
Antonio M Gotto$suffix/text()$suffix/text() & Jennifer E Moon. (2012) Safety of inhibition of cholesteryl ester transfer protein with anacetrapib: the DEFINE study. Expert Review of Cardiovascular Therapy 10:8, pages 955-963.
Read now
Read now
Alyse S Goldberg & Robert A Hegele. (2012) Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib. Drug Design, Development and Therapy 6, pages 251-259.
Read now
Read now
Keith Suckling. (2012) The landscape of drug discovery in atherosclerosis and dyslipidaemia revisited: an update of patenting activity. Expert Opinion on Therapeutic Patents 22:3, pages 199-204.
Read now
Read now
David Sullivan & Barry Lewis. (2011) A classification of lipoprotein disorders:implications for clinical management. Clinical Lipidology 6:3, pages 327-338.
Read now
Read now
Niki Katsiki, Vasilios G Athyros & Dimitri P Mikhailidis. (2011) The DEFINE study: a bright future for CETP inhibitors?. Expert Opinion on Investigational Drugs 20:3, pages 311-314.
Read now
Read now
Justin MS Lee & Robin P Choudhury. (2010) Atherosclerosis regression and high-density lipoproteins. Expert Review of Cardiovascular Therapy 8:9, pages 1325-1334.
Read now
Read now
Articles from other publishers (24)
Peter Piko, Tibor Jenei, Zsigmond Kosa, Janos Sandor, Nora Kovacs, Ildiko Seres, Gyorgy Paragh & Roza Adany. (2023) Association of CETP Gene Polymorphisms and Haplotypes with Cardiovascular Risk. International Journal of Molecular Sciences 24:12, pages 10281.
Crossref
Crossref
Xin Su, Guiyang Li, Yingjian Deng & Dong Chang. (2020) Cholesteryl ester transfer protein inhibitors in precision medicine. Clinica Chimica Acta 510, pages 733-740.
Crossref
Crossref
Alison Pottle. 2019. Advanced Practice in Endocrinology Nursing. Advanced Practice in Endocrinology Nursing
1101
1120
.
Dimitry A. Chistiakov, Andrey V. Grechko, Veronika A. Myasoedova, Alexandra A. Melnichenko & Alexander N. Orekhov. (2018) The role of monocytosis and neutrophilia in atherosclerosis. Journal of Cellular and Molecular Medicine 22:3, pages 1366-1382.
Crossref
Crossref
Vaughn A. Eyvazian & William H. Frishman. (2017) Evacetrapib. Cardiology in Review 25:2, pages 43-52.
Crossref
Crossref
Yu Kataoka, Jordan Andres, Rishi Puri, Peter Psaltis & Stephen J. Nicholls. (2016) Additional Lipid Targets to Modulate Atherosclerotic Plaques beyond LDL-C Lowering. Journal of the Japanese Coronary Association 22:4, pages 217-227.
Crossref
Crossref
Anandita P. AgarwalaAmrith RodriguesMarjorie RismanMary McCoyKevin TrindadeLiming QuMarina CuchelJeffrey BillheimerDaniel J. Rader. (2015) High-Density Lipoprotein (HDL) Phospholipid Content and Cholesterol Efflux Capacity Are Reduced in Patients With Very High HDL Cholesterol and Coronary Disease. Arteriosclerosis, Thrombosis, and Vascular Biology 35:6, pages 1515-1519.
Crossref
Crossref
Nikhilesh Arya, Mangesh D. Kharjul, Chamanlal J. Shishoo, Vishnu N. Thakare & Kishor S. Jain. (2014) Some molecular targets for antihyperlipidemic drug research. European Journal of Medicinal Chemistry 85, pages 535-568.
Crossref
Crossref
Yu Kataoka & Stephen J. Nicholls. (2014) Atherosclerotic Plaque Imaging for Evaluation of HDL Targeting Therapy. Journal of the Japanese Coronary Association 20:4, pages 282-294.
Crossref
Crossref
Maria Drakopoulou, Konstantinos Toutouzas & Christodoulos Stefanadis. (2013) Novel pharmacotherapies of familial hyperlipidemia. Pharmacology & Therapeutics 139:3, pages 301-312.
Crossref
Crossref
Brian J. Schmidt, Jason A. Papin & Cynthia J. Musante. (2013) Mechanistic systems modeling to guide drug discovery and development. Drug Discovery Today 18:3-4, pages 116-127.
Crossref
Crossref
David RhaindsBenoit J ArsenaultMathieu R BrodeurJean-Claude Tardif. (2012) An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels. Future Cardiology 8:4, pages 513-531.
Crossref
Crossref
Antonio M. GottoJr.Jr. & Jennifer E. Moon. (2012) Recent Clinical Studies of the Effects of Lipid-Modifying Therapies. The American Journal of Cardiology 110:1, pages 15A-26A.
Crossref
Crossref
R.I. Coniglio, T. Meroño, H. Montiel, M.M. Malaspina, A.M. Salgueiro, J.C. Otero, R. Ferraris, L. Schreier, F. Brites & L. Gómez Rosso. (2012) HOMA-IR and non-HDL-C as predictors of high cholesteryl ester transfer protein activity in patients at risk for type 2 diabetes. Clinical Biochemistry 45:7-8, pages 566-570.
Crossref
Crossref
Valerie Cheung & Robert A. Hegele. (2011) CETP Inhibitors: Will They Live up to Their Promise?. Current Cardiovascular Risk Reports 6:1, pages 4-11.
Crossref
Crossref
J.R. Schaefer. (2012) HDL-Spiegel oder HDL-Funktion als primäres Target der präventiven KardiologieHDL level or HDL function as the primary target in preventive cardiology. Herz 37:1, pages 51-55.
Crossref
Crossref
D E Gutstein, R Krishna, D Johns, H K Surks, H M Dansky, S Shah, Y B Mitchel, J Arena & J A Wagner. (2011) Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk Reduction. Clinical Pharmacology & Therapeutics 91:1, pages 109-122.
Crossref
Crossref
Anatol Kontush & M. John Chapman. 2011. High‐Density Lipoproteins. High‐Density Lipoproteins
423
523
.
Zahi A Fayad, Venkatesh Mani, Mark Woodward, David Kallend, Markus Abt, Tracy Burgess, Valentin Fuster, Christie M Ballantyne, Evan A Stein, Jean-Claude Tardif, James H F Rudd, Michael E Farkouh & Ahmed Tawakol. (2011) Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. The Lancet 378:9802, pages 1547-1559.
Crossref
Crossref
M. John Chapman, Henry N. Ginsberg, Pierre Amarenco, Felicita Andreotti, Jan Borén, Alberico L. Catapano, Olivier S. Descamps, Edward Fisher, Petri T. Kovanen, Jan Albert Kuivenhoven, Philippe Lesnik, Luis Masana, Børge G. Nordestgaard, Kausik K. Ray, Zeljko Reiner, Marja-Riitta Taskinen, Lale Tokgözoglu, Anne Tybjærg-Hansen & Gerald F. Watts. (2011) Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. European Heart Journal 32:11, pages 1345-1361.
Crossref
Crossref
Sridevi DevarajIshwarlal Jialal. (2011) Novel Cholesteryl Ester Transfer Protein Inhibitors: Promising Therapy for Dyslipidemia?. Metabolic Syndrome and Related Disorders 9:3, pages 163-165.
Crossref
Crossref
Ingrid C. Gelissen & Andrew J. Brown. (2011) Drug targets beyond HMG-CoA reductase: Why venture beyond the statins?. Frontiers in Biology 6:3, pages 197-205.
Crossref
Crossref
Jennifer G Robinson. (2011) Is there a future for CETP-inhibitor therapy?. Clinical Investigation 1:3, pages 367-370.
Crossref
Crossref
Abdulmaged M. Traish & Kyriakos E. Kypreos. (2011) Testosterone and cardiovascular disease: An old idea with modern clinical implications. Atherosclerosis 214:2, pages 244-248.
Crossref
Crossref